GE HealthCare Expands Photonova Spectra Trial Network
Seven sites across three continents will validate the photon-counting CT system's clinical performance.
Updated on Nov. 16, 2026 in Quantum Computing

GE HealthCare has extended its clinical and research network for Photonova Spectra, its next-generation photon-counting CT system, to seven sites across North America, Europe and Asia. The company says the programme has secured the requisite regulatory approvals and uses Deep Silicon detector technology.
Why it matters
The network gives hospital clinicians, medical physicists and GE HealthCare engineers a direct feedback loop on dose reduction, protocol design and workflow in high-volume care. The effort aims to determine whether a single scan can deliver quantitative and spectral data that would otherwise require repeat scans.
Photonova Spectra uses Deep Silicon detector technology to combine high spatial resolution with material and tissue characterisation in one workflow. Trial sites are still collecting dose reduction targets and performance metrics, and no quantitative results have been published.
The players
GE HealthCare
A global medical technology company that develops imaging, diagnostics and patient monitoring systems used in hospitals worldwide.
Stanford Medicine
The academic medical centre of Stanford University in California, known for its research in imaging and clinical medicine.
Universitätsspital Zürich
The university hospital of the University of Zurich in Switzerland, one of the largest teaching hospitals in Europe.
The details
Participating sites include Universitätsspital Zürich, which is developing dose-optimised coronary CT angiography protocols, and Rigshospitalet in Copenhagen, which is exploring paediatric and low-dose imaging. Centro Cardiologico Monzino (IRCCS) in Milan is focusing on cardiac tissue characterisation, while Stanford Medicine and the University of Wisconsin-Madison are conducting technical studies on image reconstruction and quantitative performance.
Timeline
• 16 November 2026: GE HealthCare announced the expansion of the Photonova Spectra clinical and research network.
The Tech Race
Photon-counting CT is positioned as the successor to conventional energy-integrating detector CT, and GE HealthCare's multi-site trials place it in direct competition with rival scanner makers pursuing the same technology. Validation across seven sites is an attempt to move the approach from demonstration into routine clinical adoption.
If validated, photon-counting CT could let patients receive fewer repeat scans and potentially lower radiation doses during cardiac and paediatric imaging. The trials are still at the evaluation stage, so the changes described have not yet reached routine hospital practice.
The takeaway
Clinical trials across several countries will test whether one scan can replace several, which matters for patients who face repeated imaging. Readers should watch for published dose and performance data before assuming the technology is ready for routine use.
Further reading
For related background on the physics behind detector design, see the Quantum Computing section.



